Legal & General Group
AVBP icon

Legal & General Group’s ArriVent BioPharma AVBP Stock Holding History

Legal & General Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$538K Buy
15,481
+805
+5% +$23.8K ﹤0.01% 2376
2026
Q1 		$339K Sell
14,676
-599
-4% -$13.5K ﹤0.01% 2451
2025
Q4 		$307K Buy
15,275
+485
+3% +$10.1K ﹤0.01% 2529
2025
Q3 		$273K Hold
14,790
– – ﹤0.01% 2566
2025
Q2 		$322K Buy
14,790
+1,197
+9% +$24.9K ﹤0.01% 2551
2025
Q1 		$251K Sell
13,593
-34
-0.2% -$832 ﹤0.01% 2578
2024
Q4 		$363K Buy
13,627
+10,783
+379% +$310K ﹤0.01% 2566
2024
Q3 		$66.8K Buy
2,844
+1,890
+198% +$42.9K ﹤0.01% 2763
2024
Q2 		$17.7K Buy
954
+58
+6% +$1.03K ﹤0.01% 3073
2024
Q1 		$16.1K Buy
+896
New +$18.1K ﹤0.01% 3054

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Legal & General Group's AVBP Position: Q2 2026 in Review

Legal & General Group increased its ArriVent BioPharma (AVBP) stake by 5.5% in Q2 2026, buying an estimated $23.8K and bringing the position to 15,481 shares worth $538K. The position accounts for ﹤0.01% of the portfolio, ranked #2376.

Legal & General Group first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Legal & General Group held 15,481 shares of ArriVent BioPharma worth $538K as of Q2 2026.
  • Legal & General Group bought 805 ArriVent BioPharma shares in Q2 2026, an estimated $23.8K.
  • ArriVent BioPharma made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2376 holding.
  • Legal & General Group first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.